* Genentech provides update on phase III study of Gazyva in
people with previously untreated diffuse large b-cell lymphoma
The post BRIEF-Genentech says phase III study evaluating Gazyva did not meet primary endpoint appeared first on NASDAQ.
BRIEF-Genentech says phase III study evaluating Gazyva did not meet primary endpoint
